Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relacorilant in Endogenous Cushing Syndrome (Open-Label Extension)
NCT03604198Phase 2Active, not recruiting
- Sponsor
- Corcept Therapeutics
- Start
- May 2018
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 10
01
Overview
A Phase 2 trial of relacorilant in Cushing syndrome, sponsored by Corcept Therapeutics. Started May 2018; status: active, not recruiting.
02
Drugs
relacorilant
03
Conditions
Cushing syndrome
Beyond the preview
Go deeper on NCT03604198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03604198.